Strategic Relationships

BioAtla’s strategy is to advance a large portfolio of CABs in a variety of formats that can be used individually and in combinations to best treat particular cancer indications. We are very selective in our partnerships and ideally will take our drug candidates through clinical proof of concept before partnering.


BeiGene® is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,200 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.

BioAtla® and BeiGene have entered into a global co-development and collaboration agreement for the development, manufacturing and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071). BA3071 is a novel, CTLA-4 inhibitor that is designed to be conditionally activated in the tumor microenvironment in order to reduce systemic toxicity and potentially enable safer combinations with checkpoint inhibitors such as BeiGene’s investigational anti-PD-1 antibody, tislelizumab, a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages.


Himalaya Therapeutics is a clinical stage, therapeutic company focused on developing innovative, differentiated therapies in greater china and worldwide with the goal of delivering safer, more potent cancer therapies to patients timely and cost effectively. Himalaya’s strategic approach is to manage and coordinate drug development from lead to IND to market through its internal capabilities as well as through leading contract providers and strategic partners.

Himalaya has the exclusive license from BioAtla to develop and commercialize several specific CAB candidates for the Greater China market of the PRC, Hong Kong, Macau and Taiwan, including two Phase 1/2 clinical stage assets, as well as worldwide rights to two additional preclinical drug candidates.